Eupraxia PharmaceuticalsEPRX
13F holders, Q2 2024 (June 30)8holders
$2.57avg. 13F price*
At the end of Q2 2024, 8 institutions reported holding Eupraxia Pharmaceuticals Inc. (EPRX) in their 13F filings. The largest holders were Scotia Capital Inc. ($3.5M), Royal Bank of Canada ($686K) and Bank of Montreal ($133K).
- Company
- Eupraxia Pharmaceuticals Inc.
- CUSIP
- 29842P105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 9 | $4.4M |
| Exits | 0 | $0 |
Ownership 8 holders
| Scotia Capital Inc. | 0.02% | New | 1,367,051 | $3.5M |
| Royal Bank of Canada | 0.00% | New | 265,744 | $686K |
| Bank of Montreal | 0.00% | New | 49,250 | $133K |
| UBS Group AG | 0.00% | New | 29,590 | $76K |
| 180 Wealth Advisors, LLC | 0.01% | New | 13,000 | $34K |
| JPMorgan Chase & Co. | 0.00% | New | 1,892 | $5K |
| Federation des caisses Desjardins du Quebec | 0.00% | New | 545 | $1K |
| Toronto Dominion Bank | 0.00% | New | 118 | $304 |
"% of holder's portfolio" is EPRX's weight in each manager's 13F, not the share of Eupraxia Pharmaceuticals Inc. the manager owns.